If your email program has trouble displaying this email, view as a webpage.

On November 12, the FDA Commissioner and subject matter experts from the Center for Drug Evaluation and Research discussed the agency's recent announcement regarding the removal of the "black box warning" for hormone replacement therapy. The call recording and additional resources are provided below.

Additional Resources:

• HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy | FDA
• FDA Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies | FDA
• FACT SHEET: FDA Initiates Removal of “Black Box” Warnings from Menopausal Hormone Replacement Therapy Products | HHS.gov

About Us

The Public Engagement Staff resides within the Office of External Affairs. We aim to build stronger relationships with health professional organizations, patients and patient advocacy organizations, consumer groups, trade associations, think tanks and academia, and other interested parties, in order to better inform our policy making process, identify policy hurdles or misconceptions, and create strategic collaborations. For more information, please contact us at PublicEngagement@fda.hhs.gov. For patient specific inquiries, please contact us at Patients Ask FDA.